MACA Moringa Acquisition
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
March 22, 2021 (March 3, 2021)
MORINGA ACQUISITION CORP
(Exact Name of Registrant as Specified in its Charter)
|(State or other jurisdiction||(Commission File Number)||(I.R.S. Employer|
|of incorporation)||Identification No.)|
|250 Park Avenue, 7th Floor|
|New York, NY||11040|
|(Address of Principal Executive Offices)||(Zip Code)|
Registrant’s telephone number, including area code
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
Securities registered pursuant to Section 12(b) of the Act:
|Title of each class||Trading Symbol(s)||Name of each exchange on which|
|Units, each consisting of one Class A ordinary share and one-half redeemable warrant||MACAU||The Nasdaq Stock Market LLC|
|Class A ordinary shares, par value $0.0001 per share||MACA||The Nasdaq Stock Market LLC|
|Redeemable warrants, each warrant exercisable for one Class A ordinary share at an exercise price of $11.50||MACAW||The Nasdaq Stock Market LLC|
Emerging growth company ☒
Item 8.01. Other Events.
As reported previously in Current Reports on Form 8-K filed by Moringa Acquisition Corp (the “Company”) on February 22, 2021 and March 16, 2021, the Company consummated the closings of its initial public offering (the “IPO”) on February 19, 2021 and March 3, 2021, selling 10,000,000 and 1,500,000 units to the public, on those respective dates and generating aggregate gross proceeds of $100,000,000 and $15,000,000 to the Company from those respective closings.
Substantially concurrently with the two closings of the IPO, the Company completed the private sale (the “Private Placement”) of 250,000 units and 30,000 units (the “Private Placement Units”), respectively, in the aggregate, to Moringa Sponsor US L.P. and EarlyBirdCapital, Inc. at a purchase price of $10.00 per Private Placement Unit, generating aggregate gross proceeds to the Company of $2,800,000.
Following the respective closings, a total of $100,000,000 and $15,000,000 were placed in Goldman Sachs money market funds and a JP Morgan Chase trust account, respectively.
An audited balance sheet as of March 3, 2021 reflecting receipt of the proceeds upon consummation of the IPO and the Private Placement has been issued by the Company and is included as Exhibit 99.1 to this Current Report on Form 8-K.
Item 9.01. Financial Statements and Exhibits.
|99.1||Audited Balance Sheet, as of March 3, 2021|
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: March 29, 2021
|MORINGA ACQUISITION CORP|
|By:||/s/ Gil Maman|
|Title:||Chief Financial Officer|